Atlas Trials

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Clinical trial NCT05302011 · COMPLETED

Trial details

NCT number
NCT05302011
Sponsor
Peking Union Medical College Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2020-06-01
Primary completion
2023-03-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.